Psychophysical Correlates of Pain Reduction by Topical Analgesic Compounds
2 other identifiers
observational
40
1 country
1
Brief Summary
Background: \- Researchers are studying a topical (skin) cream that reduces pain. This is called an analgesic cream. They want to try a new test to better measure how well it works. Heat will be applied to the participants arms and they will judge the intensity of the temperatures. Researchers will compare the pain reduction from this cream to other pain relief treatments. Objective: \- To better measure the effects of a pain-relieving (analgesic) cream. Eligibility: \- Healthy volunteers ages 18 50. Design:
- There will be 2 study sessions.
- Session 1 will be about 1.5 hours.
- Participants will be screened with physical exam and urine drug test. They will answer medical and psychological questions.
- Participants will have sensory testing.
- A moisturizer will be put on their arms. A heating device will be placed on their arms. It gives heat pulses of about 2 seconds each. Some are warm and some are very hot. Participants will say how strong each pulse is. They can move away if it gets painful.
- Then the pain-relieving cream will be put on one arm. The moisturizer will be put on the other. Participants will get more pulses and rate them. They will also get pairs of pulses and compare them.
- Some participants will return for session 2 for 1 hour. They will receive similar sensory testing as in session 1.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P25-P50 for all trials
Started Dec 2014
Typical duration for all trials
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
December 19, 2014
CompletedStudy Start
First participant enrolled
December 19, 2014
CompletedFirst Posted
Study publicly available on registry
December 23, 2014
CompletedPrimary Completion
Last participant's last visit for primary outcome
September 21, 2017
CompletedStudy Completion
Last participant's last visit for all outcomes
July 2, 2018
CompletedJuly 5, 2018
July 2, 2018
2.8 years
December 19, 2014
July 3, 2018
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
Thermal sensory discrimination
One time point
Eligibility Criteria
You may qualify if:
- You may be eligible to participate in this research study if you are:
- Between 18 and 50 years old.
- Fluent in English.
- Able to understand the procedures described in this document and give your written consent.
You may not qualify if:
- You may not be eligible to participate in this research study if you:
- Cannot complete the required procedures and tests in the study
- Used recreational drugs within the past six months
- Are in the third trimester of pregnancy
- Have a major medical condition or major medical history event that could affect touch and pain
- Have a medical condition that might affect touch and pain (e.g. Raynaud s Disease, peripheral neuropathy, or circulatory disorder)
- Have chronic pain or a history or chronic pain
- Have allergies to topical treatments
- Have a dermatological condition such as scars or burns, or have had a tattoo on your forearms within the previous four weeks that might influence touch or pain
- Had a recent or permanent injury of upper limbs or amputation or use a prosthetic limb
- Have participated in related NIH protocols (we will determine this)
- Used non-steroidal anti-inflammatory drugs (NSAIDS, e.g. aspirin, ibuprofen), acetaminophen, or sumatriptan within 3 days of testing (brand names include Advil, Tylenol, and Imitrex)
- Used narcotics (e.g. opioids, oxycodone) or pseudo narcotics (e.g. tramadol, tapentadol) within one week of testing (brand names include Percocet and Ultram)
- Use centrally acting medications like anticonvulsants (e.g. gabapentin, pregabalin), antidepressants (e.g. fluoxetine, duloxetine), antipsychotics (e.g. chlorpromazine, prochlorperazine), or anxiolytics (e.g. clonazepam, alprazolam) (Brand names include Neurontin, Lyrica, Prozac, Cymbalta, and Xanax)
- Use tobacco daily or used tobacco within 24 hours of testing
- +3 more criteria
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
National Institutes of Health Clinical Center, 9000 Rockville Pike
Bethesda, Maryland, 20892, United States
Study Officials
- PRINCIPAL INVESTIGATOR
Mary C Bushnell, Ph.D.
National Center for Complementary and Integrative Health (NCCIH)
Study Design
- Study Type
- observational
- Observational Model
- COHORT
- Time Perspective
- CROSS SECTIONAL
- Sponsor Type
- NIH
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
December 19, 2014
First Posted
December 23, 2014
Study Start
December 19, 2014
Primary Completion
September 21, 2017
Study Completion
July 2, 2018
Last Updated
July 5, 2018
Record last verified: 2018-07-02